Polycythaemia Vera
Also written as PV.
Conditions covered: Acute Myeloid Leukaemia · Myelodysplastic Syndromes · Chronic Myeloproliferative Disorders (CML · Polycythaemia Vera · Primary Myelofibrosis)
What our notes say
- Conditions covered: Acute Myeloid Leukaemia · Myelodysplastic Syndromes · Chronic Myeloproliferative Disorders (CML · Polycythaemia Vera · Primary Myelofibrosis) (Hematologic Malignancies and Bleeding Disorders)
Study material on Polycythaemia Vera
- Haematology End of Year 2025 Past Paper — MKU MBML 3200 Questions & Answers
- Haematology Exam 2025: MCQs on Anaemia, Leukaemia & Clotting
- Acute Leukaemia (AML/ALL) & WBC Disorders: Hematology Guide
Practice questions on Polycythaemia Vera
Polycythaemia vera is associated with which mutation in >95% of cases?
- BCR-ABL
- JAK2 V617F
- FLT3-ITD
- CALR exon 9
Answer: B. JAK2 V617F causes constitutive activation of the JAK-STAT signalling pathway, driving erythroid (and myeloid) proliferation independent of EPO. ---
Which of the following is a hallmark feature of polycythaemia vera?
- Decreased red cell mass
- Low erythropoietin levels with increased haematocrit
- Elevated erythropoietin due to hypoxia
- Pancytopenia
Answer: B. In primary polycythaemia vera, autonomous marrow proliferation (driven by JAK2 mutation) raises red cell mass while suppressing EPO via negative feedback. ---